Global Patent Index - EP 3049075 A4

EP 3049075 A4 20170503 - LAQUINIMOD COMBINATION THERAPY FOR TREATMENT OF MULTIPLE SCLEROSIS

Title (en)

LAQUINIMOD COMBINATION THERAPY FOR TREATMENT OF MULTIPLE SCLEROSIS

Title (de)

LAQUINIMOD-KOMBINATIONSTHERAPIE ZUR BEHANDLUNG VON MULTIPLER SKLEROSE

Title (fr)

TRAITEMENT COMBINÉ À BASE DE LAQUINIMOD POUR LE TRAITEMENT DE LA SCLÉROSE EN PLAQUES

Publication

EP 3049075 A4 20170503 (EN)

Application

EP 14857795 A 20140926

Priority

  • US 201361883698 P 20130927
  • US 2014057705 W 20140926

Abstract (en)

[origin: US2015094332A1] The subject invention provides a method for treating a subject afflicted with a form of multiple sclerosis (MS) or presenting a clinically isolated syndrome (CIS) comprising periodically administering to the subject an amount of laquinimod and an amount of a compound of formula (I): as described herein. The subject invention also provides packages and pharmaceutical compositions comprising laquinimod and a compound of formula (I) as described herein. The subject invention further provides uses of said compounds, pharmaceutical compositions and packages in treating a subject afflicted with a form of MS or presenting a CIS.

IPC 8 full level

A61K 31/167 (2006.01); A61K 31/4704 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01)

CPC (source: EP KR US)

A61K 9/0017 (2013.01 - KR); A61K 9/0073 (2013.01 - KR); A61K 9/12 (2013.01 - KR); A61K 9/20 (2013.01 - KR); A61K 9/48 (2013.01 - KR); A61K 31/167 (2013.01 - EP US); A61K 31/225 (2013.01 - KR US); A61K 31/4704 (2013.01 - EP KR US); A61K 45/06 (2013.01 - KR US); A61P 25/00 (2017.12 - EP); A61P 25/28 (2017.12 - EP); A61P 37/00 (2017.12 - EP); A61K 2300/00 (2013.01 - KR)

Citation (search report)

  • [Y] GIANCARLO COMI ET AL: "Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis", NEW ENGLAND JOURNAL OF MEDICINE, THE - NEJM -, vol. 366, no. 11, 15 March 2012 (2012-03-15), pages 1000 - 1009, XP055357026, ISSN: 0028-4793, DOI: 10.1056/NEJMoa1104318
  • [Y] GASPERINI CLAUDIO ET AL: "Emerging oral drugs for multiple sclerosis", EXPERT OPINION ON EMERGING DRUGS, INFORMA HEALTHCARE, UK, vol. 13, no. 3, 1 January 2008 (2008-01-01), pages 465 - 477, XP009121777, ISSN: 1472-8214, DOI: 10.1517/14728214.13.3.465
  • See references of WO 2015065628A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

DOCDB simple family (publication)

US 2015094332 A1 20150402; AR 097792 A1 20160413; AU 2014342917 A1 20160421; BR 112016006582 A2 20170801; CA 2925493 A1 20150507; CN 105848653 A 20160810; EA 201690673 A1 20160831; EP 3049075 A2 20160803; EP 3049075 A4 20170503; IL 244620 A0 20160421; JP 2016533323 A 20161027; KR 20160085757 A 20160718; MX 2016003763 A 20161028; SG 11201602175V A 20160428; TW 201601722 A 20160116; US 2016271094 A1 20160922; US 2017304253 A1 20171026; UY 35748 A 20150430; WO 2015065628 A2 20150507; WO 2015065628 A3 20151029

DOCDB simple family (application)

US 201414498024 A 20140926; AR P140103582 A 20140926; AU 2014342917 A 20140926; BR 112016006582 A 20140926; CA 2925493 A 20140926; CN 201480053575 A 20140926; EA 201690673 A 20140926; EP 14857795 A 20140926; IL 24462016 A 20160315; JP 2016516547 A 20140926; KR 20167011039 A 20140926; MX 2016003763 A 20140926; SG 11201602175V A 20140926; TW 103133660 A 20140926; US 2014057705 W 20140926; US 201615169139 A 20160531; US 201715643214 A 20170706; UY 35748 A 20140926